Imara Inc. announces expiration of HSR Act waiting period for merger with Enliven Therapeutics

Enliven Therapeutics, Inc.

HSR Act waiting period for merger with Enliven Therapeutics expired on Nov 28, 2022, without extension or request for additional information.
This expiration satisfies one of the conditions to closing the merger previously announced on Oct 13, 2022.
Upon closing, Merger Sub will merge with Enliven, making Enliven a wholly-owned subsidiary of Imara.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.